Guo CG, et al. - This systematic review with meta-analysis compared the risk of gastrointestinal bleeding (GIB) among users of third-generation P2Y₁₂ inhibitors with clopidogrel. Until September 2018, researchers systematically searched for published randomised controlled trials of ticagrelor or prasugrel vs clopidogrel. Researchers included 41 studies in the analysis of non-coronary artery bypass graft (CABG) major bleeding, 12 of which were included 58,678 patients in the GIB analysis. When compared with clopidogrel, third-generation P2Y₁₂ inhibitors were related to increased risk of GIB and non-CABG major bleeding. The findings for the upper and the unspecified GIB were consistent, but not lower GIB.